Related Experiment Video
Updated: Aug 12, 2026

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
Posterior Reversible Encephalopathy Syndrome in Children With Hematologic Malignancies
Márcio Tavares1, Mavilde Arantes2, Sérgio Chacim3
1Department of Onco Hematology, Portuguese Institute of Oncology, Porto, Portugal marcio.tavares@ipoporto.min-saude.pt.
Insights
Posterior reversible encephalopathy syndrome (PRES) can occur in children with blood cancers. While imaging often resolves, some children may develop long-term neurological issues like epilepsy, requiring close monitoring.
Area of Science:
- Pediatric Neurology
- Hematology
- Oncology
Background:
- Posterior reversible encephalopathy syndrome (PRES) is a neurological condition.
- Data on PRES in pediatric hematologic malignancies is limited.
- PRES can be associated with various predisposing factors.
Purpose of the Study:
- To describe clinical and radiologic features of PRES in children with hematologic malignancies.
- To report outcomes and follow-up of these pediatric patients.
- To highlight the importance of close monitoring for potential sequelae.
Main Methods:
- Retrospective case series.
- Analysis of clinical data, neuroimaging, and treatment outcomes.
- Median follow-up duration of 27.6 months.
Main Results:
- Ten pediatric patients diagnosed with PRES.
- Six patients received chemotherapy; four were post-allogeneic hematopoietic stem cell transplant.
- Complete radiologic resolution observed, but two patients developed secondary epilepsy.
Conclusions:
- PRES in children with hematologic malignancies can have long-term neurological consequences.
- Despite prompt diagnosis and intervention, sequelae such as epilepsy can occur.
- Close follow-up is crucial for all pediatric patients diagnosed with PRES.
Abstract:
Since its original description 2 decades ago, posterior reversible encephalopathy syndrome has been reported in children with several predisposing conditions. Epidemiologic data of posterior reversible encephalopathy syndrome in children with hematologic malignancies is still scarce. Herein, we describe the clinical and radiologic features along with the outcome and follow-up of posterior reversible encephalopathy syndrome complicating the treatment of children with hematologic malignancies. Ten patients with a median age of 6.3 years were diagnosed with posterior reversible encephalopathy syndrome. Six of them were undergoing chemotherapy and the remaining 4 were at 37, 52, 78, and 857 days after allogenic hematopoietic stem cell transplant. The median follow-up was 27.6 months. Even though follow-up imaging showed complete resolution of abnormalities in those 10 children, 2 developed secondary epilepsy. Despite accurate diagnosis of posterior reversible encephalopathy syndrome and immediate intervention, neurologic sequelae may still develop. Thus, a close follow-up should be considered in all patients.
Related Concept Videos
Rocky Mountain Spotted Fever
Hemorrhagic Stroke ll: Pathophysiology
Encephalitis l: Introduction
Encephalitis ll: Pathophysiology
Cerebral Edema ll: Pathophysiology
Hepatic Encephalopathy

